Enterprise Value
81.31M
Cash
264.2M
Avg Qtr Burn
-19.11M
Short % of Float
18.42%
Insider Ownership
24.24%
Institutional Own.
75.39%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ORIC-944 (PRC2 inhibitor) Details Prostate cancer | Phase 1b Data readout | |
ORIC-533 (CD73 Inhibitor) Details Multiple myeloma | Phase 1b Data readout | |
ORIC-114 (EGFR/HER2 Inhibitor) Details Solid tumor/s, Advanced malignancies | Phase 1b Data readout | |
Failed Discontinued | ||
ORIC-101 (Glucocorticoid Receptor Antagonist) and nab-paclitaxel Details Solid tumor/s, Spasticity, Muscle control disorder | Failed Discontinued |